Uptake of photofrin II, a photosensitizer used in photodynamic therapy, by tumour cells in vitro

• Authors: Agnieszka Chwiłkowska , Jolanta Saczko , Teresa Modrzycka , Anna Marcinkowska , Anna Malarska , Julita Bielewicz , Dorota Patalas , Teresa Banaś
• Languages of publication: EN

Abstracts

EN

Photosensitizing dyes are used in fluorescence diagnostics and photodynamic therapy (PDT). These usually hematoporphyrin derivatives (HpD) accumulate preferentially within neoplastic tissues. HpD is a mixture of ether and ester linked porphyrins. Its partially purified form is known under the commercial name of photofrin II (PII). PII emission spectra were studied in a hydrophilic (PBS) and a lipophilic (PC liposomes) environment. Red shift was observed in their emission maxima from 615 nm in buffer solution to 635 nm in lipid. Identical red shift was obtained when the intracellular fluorescence of two cancer cell lines, MCF 7 and Jurkat, incubated with PII was investigated. Thus, intramembrane localization of PII may be suggested. As determined from the total fluorescence intensity, the uptake of PII was only slightly higher for Jurkat than for MCF 7 cells. Nevertheless the kinetics of the uptake was found to be different for both cell lines.

Keywords

EN

photofrin II; photodynamic therapy; fluorescence spectra

• Publisher: Polish Biochemical Society
• Journal: Acta Biochimica Polonica
• Year: 2003
• Volume: 50
• Issue: 2
• Pages: 509-513

Dates

published

2003

received

2002-10-14

revised

2003-04-10

accepted

2003-05-08

Contributors

author

Agnieszka Chwiłkowska

• Department of Medical Biochemistry, Wrocław Medical University, Wrocław, Poland

author

Jolanta Saczko

• Department of Medical Biochemistry, Wrocław Medical University, Wrocław, Poland

author

Teresa Modrzycka

• Department of Biophysics, Wrocław Medical University, Wrocław, Poland

author

Anna Marcinkowska

• Department of Medical Biochemistry, Wrocław Medical University, Wrocław, Poland

author

Anna Malarska

• Department of Medical Biochemistry, Wrocław Medical University, Wrocław, Poland

author

Julita Bielewicz

• Department of Medical Biochemistry, Wrocław Medical University, Wrocław, Poland

author

Dorota Patalas

• Department of Medical Biochemistry, Wrocław Medical University, Wrocław, Poland

author

Teresa Banaś

• Department of Medical Biochemistry, Wrocław Medical University, Wrocław, Poland

References

• Biade S, Maziere JC, Mora L, Santus R, Morliere P, Maziere C, Salmon S, Gatt S, Dubertret L. (1992) Photosensitization by Photofrin II delivered to WI26VA4 SV40-transformed human fibroblasts by low density lipoproteins: inhibition of lipid synthesis and fatty acid uptake. Photochem Photobiol.; 55: 55-61.
• Byrne CJ, Marschallsay LV, Ward AD. (1990) The composition of photofrin II. J Photochem Photobiol B Biol.; 6: 13-27.
• Candide C, Morliere P, Maziere JC, Goldstein S, Santus R, Dubertret L, Reyftmann JP, Polonovski J. (1986) In vitro interaction of the photoactive anticancer porphyrin derivative photofrin II with low density lipoprotein, and its delivery to cultured human fibroblasts. FEBS Lett.; 207: 133-8.
• Fernandez JM, Bilgin MD, Grossweiner LI. (1997) Singlet oxygen generation by photodynamic agents. J Photochem Photobiol B: Biol.; 37: 131-40.
• Fickweiler S, Abels C, Karrer S, Baumler W, Landthaler M, Hofstadter F, Szeimies R. (1999) Photosensitization of human skin cell lines by ATMPn (9-acetoxy-2,7,12,17-tetrakis- (b-methoxyethyl)-porphycene) in vitro: mechanism of action. J Photochem Photobiol B: Biol.; 48: 27-35.
• Foster TH, Murant RS, Bryant RG, Knox RS, Gibson LS, Hlif R. (1991) Oxygen consumption and diffusion effects in photodynamic therapy. Radiat Res.; 126: 296-303.
• Furuse K, Fukuoka M, Kato H, Horai T, Kubota K, Kodama N, Kusunoki Y, Takifuji N, Okunaka T, Konaka C, Wada H, Hayata Y. (1993) A prospective phase II study on photodynamic therapy with photofrin II for centrally located early-stage lung cancer. J Clin Oncol.; 11: 1852-7.
• Geze M, Morliere P, Maziere JC, Smith KM, Santus R. (1994) Lysosomes, a key target of hydrophobic photosensitizers proposed for photochemotherapeutic applications. J. Photochem Photobiol B: Biol.; 20: 23-35.
• Korbelik M. (1993) Cellular delivery and retention of photofrin: III. Role of plasma proteins in photosensitizer clearance from cells. Photochem Photobiol.; 57: 846-50.
• Kriska T, Korecz L, Nemes I, Gal D. (1995) Physico-chemical modeling of the role of free radicals in photodynamic therapy. III. Interactions of stable free radicals with excited photosensitizers studied by kinetic ESR spectroscopy. Biochem Biophys Res Commun.; 215: 192-8.
• Ochsner M. (1997) Photophysical and photobiological processes in the photodynamic therapy of tumors. J Photochem Photobiol B: Biol.; 39: 1-18.
• Polo L, Valduga G, Jori G, Reddi E. (2002) Low-density lipoprotein receptors in the uptake of tumour photosensitizers by human and rat transformed fibroblasts. Int J Biochem Cell Biol.; 34: 10-23.
• Ricchelli F. (1995) Photophysical properties of porphyrins in biological membranes. J Photochem Photobiol B: Biol.; 29: 109-18.
• Sternberg ED, Dolphin D, Bruckner Ch. (1998) Porphyrin-based photosensitizers for use in photodynamic therapy. Tetrahedron.; 54: 4151-202.